

Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

Draft scope

Draft remit/appraisal objective

To appraise the clinical and cost effectiveness of moxetumomab pasudotox within its marketing authorisation for relapsed or refractory hairy-cell leukaemia.

Background

Hairy cell leukaemia (HCL) is a cancer of the immune system which affects white blood cells known as lymphocytes. It causes anaemia, swollen lymph nodes, spleen enlargement, unexplained weight loss and increased susceptibility to infection. There is an excess number of lymphocytes in the circulating blood. These lymphocytes are abnormal and cannot help the body to defend against infections. They are called hairy cells because the cells have fine projections on the surface which look like hairs under the microscope.

HCL is rare, representing approximately 2% of adult leukaemia.¹ Around 240 people in the UK are expected to be diagnosed with HCL each year and it is more common in men than women.¹ The five-year survival with HCL is 96.5% relative to those who do not have the disease.¹

Treatment options for HCL depend on whether patients experience symptoms. There is no NICE guidance for the treatment of HCL. The European Society for Medical Oncology recommend purine analogues cladribine and pentostatin as first line treatment of HCL. If a partial response is achieved after the first round of therapy rituximab may be added for the second round of treatment.² Patients with relapsed HCL are re-treated with the alternative purine analogue used for initial treatment with or without rituximab (an anti-CD20 monoclonal antibody) or may receive interferon alpha or bendamustine.²

The technology

Moxetumomab pasudotox (Lumoxiti, Innate Pharma) is an anti-CD22 mouse monoclonal antibody fused with a toxin. It is administered intravenously.

Moxetumomab pasudotox does not have a marketing authorisation in the UK for HCL. It has been studied in clinical trials for treating relapsed and refractory HCL after 2 previous treatments with purine analogues (or at least 1 analogue and 1 either rituximab or BRAF inhibitor) in adults.

Appendix B

Intervention(s)	Moxetumomab pasudotox
Population(s)	Adults with relapsed or refractory hairy-cell leukaemia
Comparators	<ul style="list-style-type: none"> • Interferon alpha • Bendamustine in combination with rituximab
Outcomes	<p>The outcome measures to be considered include:</p> <ul style="list-style-type: none"> • progression-free survival • overall survival • response rates • adverse effects of treatment • health-related quality of life.
Economic analysis	<p>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p> <p>The availability of any patient access schemes for the intervention or comparator technologies will be taken into account</p>
Other considerations	<p>The availability and cost of biosimilar products should be taken into account.</p> <p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p>
Related NICE recommendations and NICE Pathways	<p>Related Technology Appraisals:</p> <p>None.</p> <p>Related Guidelines:</p> <p>Haematological cancers: improving outcomes (2003). NICE guideline 47 Updated May 2016.</p> <p>Related Quality Standards:</p>

Appendix B

	<p>Haematological cancers (2017).NICE quality standard 150.</p> <p>Related NICE Pathways:</p> <p>Blood and bone marrow cancers overview (2017) NICE pathway</p>
Related National Policy	<p>The NHS Long Term Plan, 2019. NHS Long Term Plan NHS England (2018/2019) NHS manual for prescribed specialist services (2018/2019)</p> <ul style="list-style-type: none">• Blood and marrow transplantation services (adults and children) [section 29, page 98]• Specialist cancer services (adults) [section 105, page 274]. <p>Department of Health and Social Care, NHS Outcomes Framework 2016-2017 (published 2016): Domains 1-5.</p>

Questions for consultation

Where in the treatment pathway would moxetumomab pasudotox be used?

Is moxetumomab pasudotox intended to be used in people with relapsed or refractory HCL? How are relapsed and refractory defined?

Have all relevant comparators for technology X been included in the scope? Which treatments are considered to be established clinical practice in the NHS for relapsed or refractory HCL? Is vemurafenib used in the NHS?

Would moxetumomab pasudotox be used in adults with HCL who are not eligible for chemotherapy?

Is best supportive care a relevant comparator and if so, how should best supportive care be defined?

Are the outcomes listed appropriate?

Are there any subgroups of people in whom moxetumomab pasudotox is expected to be more clinically effective and cost effective or other groups that should be examined separately?

Where do you consider moxetumomab pasudotox will fit into the existing NICE pathway, [Blood and bone marrow cancers overview](#) ?

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope:

Draft scope for the proposed appraisal of moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

Issue Date: March 2020

Page 3 of 4

© National Institute for Health and Care Excellence 2020. All rights reserved.

Appendix B

- could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which moxetumomab pasudotox will be licensed;
- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;
- could have any adverse impact on people with a particular disability or disabilities.
- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;
- could have any adverse impact on people with a particular disability or disabilities.

Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts.

Do you consider moxetumomab pasudotox to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a 'step-change' in the management of the condition)?

Do you consider that the use of moxetumomab pasudotox can result in any potential significant and substantial health-related benefits that are unlikely to be included in the QALY calculation?

Please identify the nature of the data which you understand to be available to enable the Appraisal Committee to take account of these benefits.

To help NICE prioritise topics for additional adoption support, do you consider that there will be any barriers to adoption of this technology into practice? If yes, please describe briefly.

NICE intends to appraise this technology through its Single Technology Appraisal (STA) Process. We welcome comments on the appropriateness of appraising this topic through this process. (Information on the Institute's Technology Appraisal processes is available at <http://www.nice.org.uk/article/pmg19/chapter/1-Introduction>).

References

1. Haematological Malignancy Research Network. Statistics - Survival. <https://www.hmrn.org/statistics/survival> Accessed March 2020.
2. Robak et al. 2015. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, Volume 26, Issue suppl 5.